EANS-News: Swiss authorities grant product approval for IXIARO®
Vienna (Austria), July 13, 2010 (euro adhoc) -
Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information
Subtitle: Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland
Intercell AG (VSE: ICLL) announces that Swissmedic has approved IXIARO®, its vaccine against Japanese Encephalitis. IXIARO®, which is distributed and marketed by Novartis, is now available in Switzerland.
The decision by the Swiss authorities represents another important milestone for the licensure process initiated for selected attractive market segments. Intercell's vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia.
"The Swissmedic approval is great news and another important step in the product's global reach", states Thomas Lingelbach, Chief Operating Officer of Intercell.
IXIARO® is a modern purified, inactivated vaccine for active immunization of adults against infections caused by the Japanese Encephalitis Virus. IXIARO® is manufactured at Intercell's proprietary manufacturing facility in Scotland using tissue culture rather than live organisms.
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market